Trials / Completed
CompletedNCT04706845
Understanding the Burden of ACC Through the Eyes of Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 46 (actual)
- Sponsor
- Ayala Pharmaceuticals, Inc, · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a comprehensive, cross-sectional study conducted with approximately 40-60 individuals affected by ACC who may know the results of molecular profiling of their tumor. Primary Objectives: * To identify the specific burdens faced by patients with ACC * To compare/contrast the burdens faced by patients with ACC at different disease stages (no evident disease, metastatic disease/watchful waiting, progressive disease)
Detailed description
This is a comprehensive, cross-sectional study conducted with approximately 40-60 individuals affected by ACC who may know the results of molecular profiling of their tumor. Primary Objectives: * To identify the specific burdens faced by patients with ACC * To compare/contrast the burdens faced by patients with ACC at different disease stages (no evident disease, metastatic disease/watchful waiting, progressive disease) Secondary Objectives: * To assess QoL implication in patients living with ACC (Adenoid Cystic Carcinoma) * To compare the burdens and QoL impacts in people living with ACC, with their tumors bearing Notch mutations or Notch Wild Type due to: * Rate of disease progression * Location of Metastases
Conditions
Timeline
- Start date
- 2021-01-11
- Primary completion
- 2023-08-16
- Completion
- 2023-08-16
- First posted
- 2021-01-13
- Last updated
- 2023-09-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04706845. Inclusion in this directory is not an endorsement.